Monitoring HPV type-specific prevalence over time through clinic-based surveillance: A perspective on vaccine effectiveness

Vaccine

Volumn 30, Issue 11, 2012, Pages 1959-1964

  Gaffga, N H ^a   Flagg, E W ^a   Weinstock, H S ^a   Shlay, J C ^b   Ghanem, K G ^c   Koutsky, L A ^d   Kerndt, P R ^e   Hsu, K K ^f   Unger, E R ^g   Datta, S D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b DENVER PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Los Angeles Department of Health Services   (United States)

^f MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^g NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Clinic based surveillance; HPV; HPV vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER SCREENING; DRUG MONITORING; FEMALE; GENOTYPE; HEALTH SURVEY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; SAMPLE SIZE; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; AMBULATORY CARE FACILITIES; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SENTINEL SURVEILLANCE; UNITED STATES; YOUNG ADULT;

EID: 84857189619     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.021     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention (CDC). Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). March, 2007;56(RR02):1-24.
2. Garland S.M., Steben M., Sings H.L., James M., Lu Shuang Raikar R., Barr E., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. The Journal of Infectious Diseases 2009, 199:805-814.
3. Wiley D.J., Douglas J., Beutner K., Cox T., Fife K., Moscicki A., et al. External genital warts: diagnosis, treatment, and prevention. Clinical Infectious Diseases 2002, 35(Supp 2):S210-S224.
4. Gissmann L., Wolnik L., Ikenberg H., Koldovsky U., Schnurch H.G., zur H.H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proceedings of the National Academy of Sciences of the USA 1983, 80:560-563.
5. Clifford G.M., Smith J.S., Plummer M., Munoz N., Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. British Journal of Cancer 2003, 88:63-73.
6. Paavonen J., Naud P., Salmerón J., Wheeler C., Chow S., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet 2009, 374(9686):301-314.
7. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEJM 2007, 356(19):1915-1927. The FUTURE II Study Group.
8. Fairley C.K., Hocking J.S., Gurrin L.C., Chen M.Y., Donovan B., Bradshaw C.S. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women. Sexually Transmitted Infections 2009, 85:499-502.
9. Schiffman M., Kjaer S.K. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. Journal of the National Institute of Cancer Monographs No. 31 2003.
10. Moscicki A., Schiffman M., Kjaer S., Villa L.L. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 2006, 24S3. S3/42-S3/51.
11. Datta S.D., Koutsky L.A., Ratelle S., Unger E.R., Shlay J., McClain T., et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Annals of Internal Medicine 2008, 148:493-500.
12. Gravitt P.E., Peyton C.L., Apple R.J., Wheeler C.M. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. Journal of Clinical Microbiology 1998, 36(10):3020-3027.
13. Gravitt P.E., Peyton C.L., Alessi T.Q., Wheeler C.M., Coutlée F., Hildersheim A., et al. Improved amplification of genital human papillomaviruses. Journal of Clinical Microbiology 2000, 38(1):357-361.
14. Vernon S.D., Unger E.R., Williams D. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. Journal of Clinical Microbiology 2000, 38(2):651-655.
15. Clopper C.J., Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26(4):404-413.
16. Revzina N.V., DiClemente R.J. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. International Journal of STD and AIDS 2005, 16:528-537.
17. Burk R.D., Kelly P., Feldman J., Bromberg J., Vermund S.H., Dehovitz J.A., et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sexually Transmitted Diseases 1996, 23(4):333-341.
18. Dixon W.J., Massey FJ Introduction to statistical analysis 1983, McGraw-Hill, pp. 281-284. 4th ed.
19. Winer R.L., Kiviat N.B., Adam D.E., Lee S-K., Kuypers J.M., et al. Development and duration of human papillomavirus lesions after initial infection. Journal of Infectious Diseases 2005, 191:731-738.
20. Oriel J.D. Natural history of genital warts. British Journal of Venereal Diseases 1971, 47:1-12.
21. Fairley C.K., Hocking J.S., Gurrin L.C., Chen M.Y., Donovan B., Bradshaw C.S. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sexually Transmitted Infections 2009, 85:499-502.
22. Schuchat A., Bell B.P. Monitoring the impact of vaccines postlicensure: new challenges, new opportunities. Expert Review of Vaccines 2008, 7(4):437-456.
23. Markowitz L., Hariri S., Datta S.D., Dunne E., Saraiya M., Unger E. Post licensure monitoring of HPV vaccine in the United States. Vaccine 2010, 28:4731-4737.
24. Hughes J.P., Garnett G.P., Koutsky L. The theoretical population-level impact of a prophylactic human papillomavirus virus vaccine. Epidemiology 2002, 13(6):631-639.